Q-omics provides the consensus-scored BLK profile across patient tissues and cancer cell-line models. BLK expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, BLK is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, BLK RNA expression shows 15,750 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, COAD, and LSCC as cancer lineages where BLK shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BLK — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BLK survival associations across molecular data types. BLK RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BLK RNA expression–survival associations across cancer types. High BLK expression shows favorable associations in HNSC, LUAD, SKCM, CESC, BRCA and LIHC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for BLK RNA expression.
This table summarizes BLK tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 3. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for BLK. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BLK shows lower tumor expression in COAD, THCA, BLCA and LIHC and higher tumor expression in STAD and LUAD. The COAD box plot shows higher BLK RNA expression in normal versus tumor tissue (log2 FC = −1.502, t-test p < 0.001).
This table shows molecular features associated with BLK in patient tissues and cancer cell lines. In patient samples, BLK shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, BLK RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
